Nature publishes results of gene therapy treatment in phase 1/2 beta-thalassemia study
bluebird bio (formerly Genetix Pharmaceuticals Inc.) today announced publication in the journal Nature of its promising Phase 1/2 data highlighting positive results of LentiGlobin gene therapy treatment in a young adult ...
